HUP0202001D0 - - Google Patents

Info

Publication number
HUP0202001D0
HUP0202001D0 HU0202001A HUP0202001A HUP0202001D0 HU P0202001 D0 HUP0202001 D0 HU P0202001D0 HU 0202001 A HU0202001 A HU 0202001A HU P0202001 A HUP0202001 A HU P0202001A HU P0202001 D0 HUP0202001 D0 HU P0202001D0
Authority
HU
Hungary
Application number
HU0202001A
Other languages
Hungarian (hu)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Priority to HU0202001A priority Critical patent/HUP0202001A2/hu
Publication of HUP0202001D0 publication Critical patent/HUP0202001D0/hu
Priority to PL03372799A priority patent/PL372799A1/xx
Priority to DE60335717T priority patent/DE60335717D1/de
Priority to US10/518,114 priority patent/US7781455B2/en
Priority to EA200500017A priority patent/EA008166B1/ru
Priority to BR0311771-5A priority patent/BR0311771A/pt
Priority to MXPA04012691A priority patent/MXPA04012691A/es
Priority to EP03738355A priority patent/EP1517907B1/en
Priority to JP2004513288A priority patent/JP4502804B2/ja
Priority to HR20050027A priority patent/HRP20050027A2/hr
Priority to PCT/HU2003/000041 priority patent/WO2003106456A2/en
Priority to AU2003244880A priority patent/AU2003244880B2/en
Priority to AT03738355T priority patent/ATE495162T1/de
Priority to CNB038138581A priority patent/CN100347170C/zh
Priority to NZ537633A priority patent/NZ537633A/en
Priority to KR1020047020277A priority patent/KR100756761B1/ko
Priority to YUP-1091/04A priority patent/RS109104A/sr
Priority to IL16543404A priority patent/IL165434A0/xx
Priority to ZA200409907A priority patent/ZA200409907B/en
Priority to IS7638A priority patent/IS7638A/is
Priority to NO20050199A priority patent/NO20050199L/no
Publication of HUP0202001A2 publication Critical patent/HUP0202001A2/hu
Priority to US12/831,771 priority patent/US20110118305A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HU0202001A 2002-06-14 2002-06-14 DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok HUP0202001A2 (hu)

Priority Applications (22)

Application Number Priority Date Filing Date Title
HU0202001A HUP0202001A2 (hu) 2002-06-14 2002-06-14 DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok
YUP-1091/04A RS109104A (sr) 2002-06-14 2003-06-11 Azabiciklo-oktan i derivati nonana sa aktivnošću inhibicije ddp-iv
PCT/HU2003/000041 WO2003106456A2 (en) 2002-06-14 2003-06-11 New compounds
AT03738355T ATE495162T1 (de) 2002-06-14 2003-06-11 Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
US10/518,114 US7781455B2 (en) 2002-06-14 2003-06-11 Compounds
EA200500017A EA008166B1 (ru) 2002-06-14 2003-06-11 Производные азобициклооктанов и нонанов, обладающие активностью в ингибировании dpp-iv
BR0311771-5A BR0311771A (pt) 2002-06-14 2003-06-11 Derivados de nonano e azabiciclo-octano com atividade inibitória da ddp-iv
MXPA04012691A MXPA04012691A (es) 2002-06-14 2003-06-11 Derivados de azabiciclo-octano y nonano con actividad inhibitoria de dpp-iv.
EP03738355A EP1517907B1 (en) 2002-06-14 2003-06-11 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
JP2004513288A JP4502804B2 (ja) 2002-06-14 2003-06-11 Ｄｄｐ−ｉｖ阻害活性を有するアザビシクロ−オクタン及びノナン誘導体
HR20050027A HRP20050027A2 (en) 2002-06-14 2003-06-11 Azabicyclo-octane and nonane derivatives with ddp-iv inhibiting activity
PL03372799A PL372799A1 (en) 2002-06-14 2003-06-11 New compounds
AU2003244880A AU2003244880B2 (en) 2002-06-14 2003-06-11 Azabicyclo-octane and nonane derivatives with DDP-IV inhibiting activity
DE60335717T DE60335717D1 (de) 2002-06-14 2003-06-11 Azabicyclo-octan und nonan derivate mit ddp-iv hemmender wirkung
CNB038138581A CN100347170C (zh) 2002-06-14 2003-06-11 具有dpp－iv抑制活性的氮杂二环辛烷与壬烷衍生物
NZ537633A NZ537633A (en) 2002-06-14 2003-06-11 Azabicyclo-octane and nonane derivatives with DDP-IV inhibiting activity
KR1020047020277A KR100756761B1 (ko) 2002-06-14 2003-06-11 Ｄｄｐ-ｉｖ 억제 활성을 지닌 아자비시클로-옥탄 및 노난유도체
IL16543404A IL165434A0 (en) 2002-06-14 2004-11-29 Compounds having DPP-IV inhibitory activity
ZA200409907A ZA200409907B (en) 2002-06-14 2004-12-07 Azabicyclo-octane and nonane derivatives with DDP-IV inhibiting activity
IS7638A IS7638A (is) 2002-06-14 2005-01-12 Asabísýkló-oktan- og nónanafleiður með DDP-IV tálmunarvirkni
NO20050199A NO20050199L (no) 2002-06-14 2005-01-13 Azadisyklo-oktan og nonanderivater med DDP-IV-inhiberende aktivitet
US12/831,771 US20110118305A1 (en) 2002-06-14 2010-07-07 Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0202001A HUP0202001A2 (hu) 2002-06-14 2002-06-14 DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok

Publications (2)

Publication Number Publication Date
HUP0202001D0 true HUP0202001D0 (enExample) 2002-08-28
HUP0202001A2 HUP0202001A2 (hu) 2005-08-29

Family

ID=90001551

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202001A HUP0202001A2 (hu) 2002-06-14 2002-06-14 DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok

Country Status (21)

Country Link
US (2) US7781455B2 (enExample)
EP (1) EP1517907B1 (enExample)
JP (1) JP4502804B2 (enExample)
KR (1) KR100756761B1 (enExample)
CN (1) CN100347170C (enExample)
AT (1) ATE495162T1 (enExample)
AU (1) AU2003244880B2 (enExample)
BR (1) BR0311771A (enExample)
DE (1) DE60335717D1 (enExample)
EA (1) EA008166B1 (enExample)
HR (1) HRP20050027A2 (enExample)
HU (1) HUP0202001A2 (enExample)
IL (1) IL165434A0 (enExample)
IS (1) IS7638A (enExample)
MX (1) MXPA04012691A (enExample)
NO (1) NO20050199L (enExample)
NZ (1) NZ537633A (enExample)
PL (1) PL372799A1 (enExample)
RS (1) RS109104A (enExample)
WO (1) WO2003106456A2 (enExample)
ZA (1) ZA200409907B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20033521A3 (en) 2001-06-27 2004-05-12 Smithklineábeechamácorporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
CN1764458A (zh) 2003-03-26 2006-04-26 麦克公司 作为黑皮质素－4受体激动剂的双环哌啶衍生物
WO2004103993A1 (en) 2003-05-14 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
AU2004265341A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
HU227684B1 (en) 2003-08-29 2011-11-28 Sanofi Aventis Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors
EP1712547B1 (en) 2004-02-05 2011-12-14 Kyorin Pharmaceutical Co., Ltd. Bicycloester derivative
US7560569B2 (en) 2004-02-18 2009-07-14 Kyorin Pharmaceutical Co., Ltd Bicycloamide derivative
JP4689599B2 (ja) * 2004-02-27 2011-05-25 杏林製薬株式会社 ビシクロ誘導体
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
CN101084211A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为治疗剂的用途
JP4958784B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼ酵素によって媒介される疾患の処置のための複素環誘導体
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
BRPI0608469A2 (pt) 2005-04-22 2010-01-05 Alantos Pharmaceuticals Holding Inc inibidores de dipeptidil peptidase-iv
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
CA2617715A1 (en) * 2005-08-11 2007-02-15 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a dpp-iv inhibitor
WO2007022502A2 (en) * 2005-08-19 2007-02-22 Elan Pharmaceuticals, Inc. Bridged n-cyclic sulfonamido inhibitors of gamma secretase
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
CA2645154C (en) 2006-03-08 2011-11-29 Kyorin Pharmaceutical Co., Ltd. Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PE20080344A1 (es) 2006-06-27 2008-06-09 Sanofi Aventis Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
PE20080212A1 (es) 2006-06-27 2008-04-25 Sanofi Aventis Derivados de ureas de piperidina o pirrolidina como moduladores de la 11b-hidroxiesteroide deshidrogenasa tipo 1 (11bhsd1)
FR2902791B1 (fr) * 2006-06-27 2008-08-22 Sanofi Aventis Sa Derives d'urees de tropane,leur preparation et leur application en therapeutique
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
JPWO2008114857A1 (ja) 2007-03-22 2010-07-08 杏林製薬株式会社 アミノアセチルピロリジンカルボニトリル誘導体の製造方法
GB0713602D0 (en) * 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT2074120E (pt) * 2007-10-25 2010-06-15 Exelixis Inc Compostos de tropano
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
CA2732984A1 (en) 2008-08-07 2010-02-11 Kyorin Pharmaceutical Co., Ltd. Process for production of bicyclo[2.2.2]octylamine derivative
CN102186474A (zh) * 2008-08-14 2011-09-14 杏林制药株式会社 稳定的医药组合物
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
PT2470552E (pt) 2009-08-26 2014-01-30 Sanofi Sa Novos hidratos de fluoroglicósido heteroaromáticos cristalinos, fármacos compreendendo estes compostos e sua utilização
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130023494A1 (en) 2010-04-06 2013-01-24 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
IN2015DN03795A (enExample) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2016144862A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL59004A0 (en) * 1978-12-30 1980-03-31 Beecham Group Ltd Substituted benzamides their preparation and pharmaceutical compositions containing them
JPS5592384A (en) * 1978-12-30 1980-07-12 Beecham Group Ltd Compound having pharmacological activity
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
WO2001034594A1 (en) * 1999-11-12 2001-05-17 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
EP1254113A1 (en) * 2000-01-24 2002-11-06 Novo Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
TW583185B (en) 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
PT1323710E (pt) 2000-10-06 2008-11-25 Mitsubishi Tanabe Pharma Corp Compostos azotados com anel de cinco membros
JP4357293B2 (ja) * 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
HUP0200849A2 (hu) * 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra

Also Published As

Publication number Publication date
NO20050199L (no) 2005-03-04
US20110118305A1 (en) 2011-05-19
CN1662530A (zh) 2005-08-31
ATE495162T1 (de) 2011-01-15
ZA200409907B (en) 2006-08-30
KR100756761B1 (ko) 2007-09-07
DE60335717D1 (de) 2011-02-24
AU2003244880A1 (en) 2003-12-31
KR20050016551A (ko) 2005-02-21
AU2003244880B2 (en) 2009-05-28
NZ537633A (en) 2006-08-31
IL165434A0 (en) 2006-01-15
US20050153973A1 (en) 2005-07-14
EP1517907A2 (en) 2005-03-30
JP2005532369A (ja) 2005-10-27
JP4502804B2 (ja) 2010-07-14
PL372799A1 (en) 2005-08-08
WO2003106456A2 (en) 2003-12-24
RS109104A (sr) 2007-02-05
EA200500017A1 (ru) 2005-06-30
HRP20050027A2 (en) 2006-02-28
CN100347170C (zh) 2007-11-07
WO2003106456A3 (en) 2004-03-04
EA008166B1 (ru) 2007-04-27
HUP0202001A2 (hu) 2005-08-29
MXPA04012691A (es) 2005-08-15
BR0311771A (pt) 2005-03-29
EP1517907B1 (en) 2011-01-12
IS7638A (is) 2005-01-12
US7781455B2 (en) 2010-08-24

Similar Documents

Publication Publication Date Title
BE2019C547I2 (enExample)
BE2019C510I2 (enExample)
BE2018C021I2 (enExample)
BE2017C049I2 (enExample)
BE2017C005I2 (enExample)
BE2016C069I2 (enExample)
BE2016C040I2 (enExample)
BE2016C013I2 (enExample)
BE2015C078I2 (enExample)
BE2016C002I2 (enExample)
BE2018C018I2 (enExample)
BE2015C017I2 (enExample)
BE2014C053I2 (enExample)
BE2014C051I2 (enExample)
BE2014C041I2 (enExample)
BE2014C030I2 (enExample)
BE2014C016I2 (enExample)
BE2014C015I2 (enExample)
BE2013C063I2 (enExample)
BE2013C039I2 (enExample)
JP2002330976A5 (enExample)
BE2011C038I2 (enExample)
BE2015C068I2 (enExample)
BE2013C046I2 (enExample)
BR0315835A2 (enExample)

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished